tiziana-logo.png
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
27 févr. 2025 08h00 HE | Tiziana Life Sciences Ltd.
Traumatic brain injury is a leading cause of death and disabilityCurrently, there is no treatment to prevent the long-term effects of traumatic brain injuryFindings could translate into treating...
1-primary-large-dark.jpg
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
16 sept. 2024 07h00 HE | Abata
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
1-primary-large-dark.jpg
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
22 août 2024 07h00 HE | Abata
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
1-primary-large-dark.jpg
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
15 août 2024 07h00 HE | Abata
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline
1-primary-large-dark.jpg
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis
09 juil. 2024 06h00 HE | Abata
Abata Therapeutics Announces FDA Clearance of Investigational New Drug Application for Clinical Evaluation of ABA-101 in Progressive Multiple Sclerosis